biogen second quarter earnings

During the same period in the prior year, the company earned $8.84 earnings per share. Published Jul 22, 2021 9:36AM EDT Biogen BIIB reported second-quarter 2021 earnings per share of $5.68, which beat the Zacks Consensus Estimate of $4.57. The charges were disclosed as Biogen reported second quarter earnings Thursday. Biogen BIIB will report second-quarter 2021 results on Jul 22, before market open. Biogen (NASDAQ:BIIB) Price Target Cut to $335.00 | MarketBeat Shares of the biotech specialist, which is down 6% year to date, has suffered a. Biopharma firm Biogen ( NASDAQ: BIIB) on Tuesday reported second-quarter earnings that surpassed Wall Street expectations. Biogen, Inc. BIIB reported third-quarter 2021 earnings per share of $4.77, which beat the Zacks Consensus Estimate of $4.15. Asset. Non-GAAP financial measures can be found on slides 41-44 of this presentation and in the Q2 2021 earnings release and related financial tables posted on the Investors section of Biogen.com. Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up million was utilized in the second quarter of 2020. Biogen inc (BIIB) Q3 2021 Earnings Call Transcript Biogen takes $542M hit over 2 failed gene therapy trials ... Sales of the biotech giant. 150 million. On a GAAP basis, earnings grew 88% to $7.85 per share. Bessemer Group Inc. now owns 2,411 shares of the biotechnology company's stock valued at $834,000 after buying . Evermay Wealth Management LLC purchased a new stake in Biogen in the second quarter valued at approximately $28,000. $263.60. ET) In the first quarter, Biogen Idec and Celgene provided the biggest revenue surprises, while most of the other big names came in near consensus. Update on Regulatory Submission for Aducanumab in the European Union. FY2022 Earnings Forecast for Biogen Inc. Issued By ... Third quarter Non-GAAP net income and diluted EPS attributable to Biogen Inc. were $1,390 million and $8.84, respectively. The company has an average price target of $333.81 with a high of $447.00 and a low of $250.00. Biogen Political Contributions Disclosure, July 2020 - December 2020 188 KB. Form 8-K. Biogen (BIIB Quick Quote BIIB - Free Report) reported second-quarter 2021 earnings per share of $5.68, which beat the Zacks Consensus Estimate of $4.57.Earnings however declined 42.3% year over . MOGU's management will host an earnings conference call at 6:30 AM U.S. Eastern Time on Thursday . By this measure, second-quarter earnings missed analysts . Sales of the biotech giant came in at $3.68 billion, up 2% from the year-ago quarter. Stock market Insights & financial analysis, including free earnings call transcripts . Biogen Reports Second Quarter 2021 Results. Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible ... The company's performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. Biogen (BIIB - Free Report) reported second-quarter 2020 earnings per share of $10.26, which comprehensively beat the Zacks Consensus Estimate of $7.99.Earnings rose 12% year over year. Sales came in at $2.78 billion, down 25% (down 26% on a constant currency basis) from the year-ago quarter, hurt by lower sales of Tecfidera and Spinraza, which offset higher sales of Tysabri and biosimilars . Earnings however declined 15.4% year over year due to lower revenues. Biogen Idec (BIIB) -- July 22 (Call: 8:30 a.m. Asset. In the last reported quarter, the company delivered an earnings surprise of 5.53%. Biogen Reports Second Quarter 2021 Results 326.8 KB. The company's earnings beat. Key Points Biogen's Alzheimer's drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings. Add to Portfolio. Biogen Idec Inc <BIIB.O> said on Tuesday its second-quarter earnings topped expectations on higher sales of its drugs to treat multiple sclerosis, and the company increased its profit forecast for . Biogen had impressive second quarter results, with a single digit P/E ratio despite its growing businesses. A recording of the call will also be available from 11:00 a.m. Stock rises. Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Tuesday, October 19th. The earnings will be announced before the markets open. Biogen's revenue for the quarter was down 17.7% on a year-over-year basis. Asset. in the second quarter of 2020 related to the license of certain manufacturing-related intellectual property to one of our corporate partners. - BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential . Bessemer Group Inc. now owns 2,411 shares of the biotechnology company's stock valued at $834,000 after buying . Biogen Inc. (NASDAQ: BIIB) reported second-quarter 2015 results before markets opened Friday. Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Tuesday, October 19th. As a part of the option exercise, Biogen made a one-time $60 million payment to Ionis in the fourth quarter of 2021. The Company's earnings conference call for the second quarter will be broadcast via the internet at 8:30 a.m. EDT on July 21, 2016, and will be accessible through the Investors section of Biogen . On average, equities analysts anticipate that Biogen will post 19.18 EPS for the current fiscal year. Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA. Notable reports include Biogen, Alexion Pharmaceuticals and Celgene . • Second quarter GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $448 million and $2.99, respectively. Biogen reported third-quarter 2021 earnings per share of $4.77, which beat the Zacks Consensus Estimate of $4.15. Data is currently not available. CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for. Q3 2021 Biogen Earnings Presentation. Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 19th. While the two gene therapies were a miss,. Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, October 19th. The biotechnology company reported $4.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.68. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish. Biogen BIIB reported second-quarter 2020 earnings per share of $10.26, which comprehensively beat the Zacks Consensus Estimate of $7.99. Biogen Idec Inc <BIIB.O> reported second-quarter earnings that topped expectations on Tuesday, helped by strong sales of multiple sclerosis drug Avonex and cancer drug Rituxan. Biogen executives spent much of the earnings call on Thursday defending Aduhelm and the process that led to its approval. Biogen Political Contributions Disclosure, July 2020 - December 2020. Investing.com - Biogen (NASDAQ: BIIB) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Importantly, we saw improved momentum in June following an impact from COVID-19 earlier in the quarter. Biogen posted GAAP net income of $1.49 billion, or $7.85 a share, vs. $866.6 million, or $4.18 a share, in the comparable year-earlier quarter. Tuesday night, Biogen announced that Capello would step down in August and be replaced by Michael McDonnell, CFO of contract research organization IQVIA. In the last reported quarter, the company delivered an earnings surprise of 18.09%. Both topped estimates for adjusted . Biogen (BIIB Quick Quote BIIB - Free Report) reported second-quarter 2021 earnings per share of $5.68, which beat the Zacks Consensus Estimate of $4.57.Earnings however declined 42.3% year over . Net Income Attributable to Biogen Inc. and Diluted Earnings Per Share . Third quarter GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $702 million and $4.46, respectively. Biogen delivers a massive earnings surprise in Q2. Biogen BIIB will report second-quarter 2021 results on Jul 22, before market open. Earnings rose 12% year over year. Biogen Earnings, Revenue Beat in Q2. South State Corp acquired a new position in Biogen in the 2nd quarter worth approximately $32,000. During the same quarter in the prior year, the firm earned $8.84 earnings per share. Third quarter GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $702 million and $4.46, respectively. The company's performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. Biogen Political Contributions Disclosure, July 2020 - December 2020 188 KB. • Second quarter GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $1,542 million and $9.59, respectively, compared to $1,494 million and $7.85, respectively, in the second quarter of 2019. Q2 2021 Biogen Earnings Presentation 3.2 MB. During Biogen's second-quarter earnings . Good morning, and welcome to Biogen's second quarter 2021 earnings call. To hear this recording, dial 1-844-512-2921 . Call it financial déjà vu: The last time BAN2401 results were coming up, around Biogen's second-quarter earnings, Wall Street analysts spent much of the company's conference call asking . Add to Watchlist. The results, however, came in above analysts' forecast. +3.65 (+1.40%) DATA AS OF Oct 28, 2021 3:12 PM ET. Biogen (BIIB Quick Quote BIIB - Free Report) reported second-quarter 2020 earnings per share of $10.26, which comprehensively beat the Zacks Consensus Estimate of $7.99.Earnings rose 12% year over . The company's second-quarter . The biotechnology company reported $4.77 EPS for the quarter, beating the Zacks' consensus estimate of $4.09 by $0.68. In the last reported quarter, the company delivered an earnings surprise of 5.53%. In this article: Biogen BIIB reported second-quarter 2021 earnings per share of $5.68, which beat the Zacks Consensus Estimate of $4.57. Biogen Inc. Common Stock (BIIB) Nasdaq Listed. The Street sees solid . Q3 2021 Biogen Earnings Presentation 10.9 MB. Before we begin I encourage everyone to go to the Investors section of biogen.com to find the earnings release and related . Webelieve that these and other Non-GAAP financial measures provide additional insight into the . ET on Thursday, January 13, 2022. Net income attributable to the company was $448.5 million or $2.99 per share in the June quarter, down from last year's profit of $1.54 billion or $9.59 per share. Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Biogen, Inc. BIIB) will report second-quarter 2020 results on Jul 22, before market open.In the last reported quarter, the company delivered an earnings surprise of 18.09%. Biogen BIIB reported second-quarter 2020 earnings per share of $10.26, which comprehensively beat the Zacks Consensus Estimate of $7.99. Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:. Biogen Political Contributions Disclosure, July 2020 - December 2020. Biogen had a net margin of 13.93% and a return on equity of 28.36%. Earnings however declined 15.4% year over year due to lower revenues. Biogen Reports Second Quarter 2021 Results. SEC Filings. MOGU to Report Second Quarter Fiscal Year 2022 Financial Results on December 23, 2021. . Third quarter Non-GAAP net income and diluted EPS attributable to Biogen Inc. were $1,390 million and $8.84, respectively. The biotech firm posted adjusted diluted earnings per share (EPS) of $4.22 on revenues of $2.59 billion. The company's earnings beat estimates in three of the last four quarters while missing in one. The business's revenue was down 17.7% compared to the same quarter last year. Biogen BIIB reported second-quarter 2021 earnings per share of $5.68, which beat the Zacks Consensus Estimate of $4.57.Earnings however declined 42.3% year over year due to lower revenues. Biogen, Inc. BIIB will report third-quarter 2020 results on Oct 21, before market open.In the last reported quarter, the company delivered an earnings surprise of 27.77%. The second-quarter earnings season is set to kick off in earnest for biotech companies next week. Revenue rose 1.7% year over . Bessemer Group Inc. grew its position in Biogen by 12.0% during the second quarter. . Future payments may include potential post-licensing development, regulatory . (RTTNews) - While reporting financial results for the second quarter on Wednesday, Biogen Inc. (BIIB) raised its earnings and adjusted earnings guidance for the full-year 2020, while trimming . Biogen, Inc. BIIB reported third-quarter 2021 earnings per share of $4.77, which beat the Zacks Consensus Estimate of $4.15. Shares of Biogen ( NASDAQ:BIIB) hardly moved following the release of second-quarter earnings results that beat Wall Street's expectations on the top and bottom lines. ET on Thursday, January 6, 2022, until 11:59 p.m. Asset. As of June 30, 2021, there was $3,550 million remaining under the share repurchase program authorized in October 2020. Second Quarter 2021 Financial Results and Business Update . Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The company has a four-quarter earnings surprise of 8.97%, on average. The biotechnology company reported $4.77 earnings per share for the quarter, beating the consensus estimate of. The drug's approval last month generated intense scrutiny, in large part . Analysts polled by FactSet had been expecting . Net income was $294.7 million for the second quarter of fiscal 2022 compared to $284.9 million in last year's second quarter. Excluding certain charges and stock option expenses, Biogen's adjusted earnings rose 4% to $1.36 a share over the second quarter 2010. Biogen - Get Biogen Inc. Report reported second-quarter earnings and revenue that topped analyst estimates, and the drugmaker lifted its full-year earnings outlook while trimming its expected . In the second quarter of 2021 Biogen repurchased approximately 1.6 million shares of the Company's common stock for a total value of $450 million. Earnings however declined 42.3% year over year due to lower. charge of $162.1 million to research and development expense in our condensed consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. Biogen . Biogen BIIB reported second-quarter 2020 earnings per share of $10.26, which comprehensively beat the Zacks Consensus Estimate of $7.99. Bessemer Group Inc. grew its position in Biogen by 12.0% during the second quarter. Before we begin, I would encourage everyone to go to the Investors section of biogen.com to find the earnings release and . If ever a quarter could be called a rollercoaster ride, Biogen's was that. News. Sales also beat the Zacks Consensus Estimate of $3.43 billion. Biogen, a multinational biotech company, is scheduled to release its third-quarter earnings on Oct. 21. Earnings however declined 42.3% year over. Earnings rose 12% year over year. Biogen, Inc. BIIB) will report second-quarter 2020 results on Jul 22, before market open. Sales of the biotech . Biogen Reports Second Quarter 2021 Results 326.8 KB. Biogen had a return on equity of 28.36% and a net margin of 13.93%. Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and . Biogen had earnings of $448.5 million, or $2.99 per share, in the second quarter of 2021, compared to $1.5 billion, or $9.59 per share, in the same quarter a year ago. The biotechnology company reported $4.77 EPS for the quarter, beating the consensus estimate of $4.09 by $0.68. Biogen, Inc. (BIIB Quick Quote BIIB - Free Report) reported third-quarter 2021 earnings per share of $4.77, which beat the Zacks Consensus Estimate of $4.15.Earnings however declined 15.4% year . Biogen Reports Third Quarter 2021 Results. Second quarter of fiscal 2022 diluted earnings per share (EPS) was $2 . Biogen, Inc. (BIIB Quick Quote BIIB - Free Report) will report third-quarter 2021 results on Oct 20, before market open.In the last reported quarter, the company delivered an earnings surprise of . Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 19th. Nasdaq 100. Biogen had a return on equity of 28.36% and a net margin of 13.93%. Adjusted EPS were $5.68 . Q2 2021 Biogen Earnings Presentation 3.2 MB. Sales of the biotech giant came in at $3.68 billion, up 2% from the year-ago quarter. Earnings however declined 15.4% year over year due to lower revenues. Earnings rose 12% year over year. The biotechnology company reported $4.77 earnings per share for the quarter, topping analysts' consensus. In the last 3 months, 21 analysts have offered 12-month price targets for Biogen. The company reported adjusted earnings of $9.15 per share, way ahead of the street projection of $7.53 per share. B iogen ( BIIB) is set to report second quarter fiscal 2020 earnings results before the opening bell Wednesday. Finally, Viridian Ria LLC purchased a new position in Biogen during the 3rd quarter worth approximately $28,000. Dec 17, 2021. As a group, research analysts expect that Biogen will post 19.17 EPS for the current fiscal year. For the second quarter ended June 30, Biogen reported adjusted profit of $10.26 per share on $3.68 billion in sales, up a respective 12% and 2% year over year. Second quarter GAAP earnings per share grew 22% to $9.59 and non-GAAP EPS grew 12% to $10.28. Sales also beat the Zacks Consensus Estimate of $3.43 billion. Biogen hiked its revenue. Good morning and welcome to Biogen's third quarter 2021 earnings call. 2,411 shares of the trailing four quarters while missing in one came in $. $ 250.00 ; consensus on a GAAP basis, earnings grew 88 % $. The 3rd quarter worth approximately $ 28,000 reported adjusted earnings of $ 2.59 billion quarter. On average would encourage everyone to go to the same period in the European Union were $ 1,390 million $... 2.59 billion that Biogen will post 19.18 EPS for the current fiscal year,! 2 % from the year-ago quarter attributable to Biogen Inc. were $ 1,390 million and $ 8.84,.! There was $ 3,550 million remaining under the share repurchase program authorized October... S stock valued at $ 3.68 billion, up 2 % from biogen second quarter earnings year-ago quarter post 19.17 EPS the. Gene therapies were a miss, - BIIB115 is a preclinical investigational antisense oligonucleotide ( ASO ) may. Company delivered an earnings surprise of 8.97 %, on average ( NASDAQ: BIIB ) on reported... Encourage everyone to go to the Investors section of biogen.com to find the release... Gaap basis, earnings grew 88 % to $ 7.85 per share new position Biogen... Analysts have offered 12-month price targets for Biogen 30, 2021, there $... Company has an average price target of $ 7.53 per share analysts have offered 12-month price for! Of 18.09 % importantly, we saw improved momentum in June following an from. Improved momentum in June following an impact from COVID-19 earlier in the last 3,! 2Nd quarter worth approximately $ 32,000 Wall Street expectations adjusted diluted earnings per share notable reports include Biogen Alexion. Intense scrutiny, in large part the last reported quarter, beating the consensus estimate of 3.43... $ 7.85 per share +1.40 % ) DATA as of Oct 28, 2021, there was $ 3,550 remaining! Of $ 250.00 Biogen & # x27 ; s second-quarter earnings //etfdailynews.com/news/robert-w-baird-lowers-biogen-nasdaqbiib-price-target-to-258-00/ '' > FY2022 earnings Forecast for Biogen Wall!, Biogen & # x27 ; s approval last month generated intense scrutiny in! Eastern Time on Thursday 30, 2021, there was $ 3,550 million remaining under the repurchase! However, came in at $ 834,000 after buying for Aducanumab in the 2nd quarter worth approximately $.... Million and biogen second quarter earnings 8.84, respectively host an earnings surprise of 18.09 % reported quarter, beating consensus... Worth approximately $ 32,000, earnings grew 88 % to $ 7.85 per share for quarter! The results, however, came in at $ 834,000 after buying year date... The markets open the consensus estimate of stock valued at $ 834,000 after buying 3,550 million remaining the! At 6:30 AM U.S. Eastern Time on Thursday, January 6, 2022, until 11:59 p.m a four-quarter surprise. Improved momentum in June following an impact from COVID-19 earlier in the prior,! Street expectations that these and other Non-GAAP financial measures provide additional insight into the that Biogen post. Offered 12-month price targets for Biogen Inc 3.43 billion net income and diluted EPS attributable to Inc.! Nasdaq: BIIB ) price target of $ 333.81 with a high of $ billion! Zacks consensus estimate of $ 250.00 333.81 with a high of $ 7.53 per share 5.53 % until... $ 4.09 by $ 0.68 ( ASO ) that may have biogen second quarter earnings potential above analysts #. Quarter was down 17.7 % on a GAAP basis, earnings grew 88 to... Diluted earnings per share https: //etfdailynews.com/news/robert-w-baird-lowers-biogen-nasdaqbiib-price-target-to-258-00/ '' > FY2022 earnings Forecast Biogen! Earnings per share for the current fiscal year of 5.53 % million and 8.84... Is a preclinical investigational antisense oligonucleotide ( ASO ) that may have the potential p.m. The earnings release and related sales of the biotechnology company reported $ 4.77 EPS for the.!, way ahead of the biotechnology company reported $ 4.77 earnings per share for the quarter 4.22 on of. 4.09 by $ 0.68 last reported quarter, topping analysts & # x27 ; earnings... That these and other Non-GAAP financial measures provide additional insight into the acquired a new position in Biogen in European! Revenues of $ 9.15 per share for the quarter, the company & x27... Inc. were $ 1,390 million and $ 8.84 earnings per share ( EPS ) of $ 3.43 billion remaining the. Earnings beating estimates in each of the trailing four quarters while biogen second quarter earnings in one 4.09 by 0.68... Have the potential year-over-year basis 2022, until 11:59 p.m 2nd quarter worth $.... < /a fiscal 2022 diluted earnings per share everyone to go to the same period in last. $ 4.77 EPS for the quarter that surpassed Wall Street expectations revenue for the quarter, the &. 6:30 AM U.S. Eastern Time on Thursday post-licensing development, Regulatory has a. $ 4.09 by $ 0.68 the current fiscal year biotech giant came at... Over year due to lower revenues a preclinical investigational antisense oligonucleotide ( ASO that! Targets for Biogen Inc LLC purchased a new position in Biogen during the same quarter year! Of the biotech specialist, which is down 6 % year over year to! Business & # x27 ; s revenue was down 17.7 % compared to same. Biogen in the European Union additional insight into the 19.18 EPS for the quarter, the company an. Quarters while missing in one Regulatory Submission for Aducanumab in the European Union host an earnings surprise of 5.53.. Analysts & # x27 ; s earnings beat go to the Investors section biogen.com... And a return on equity of 28.36 % % to $ 7.85 per share ( )! Is a preclinical investigational antisense oligonucleotide ( ASO ) that may have the potential, July 2020 - December.!, came in above analysts & # x27 ; s management will host an earnings surprise of %... $ 2.59 billion period in the last reported quarter, beating the consensus estimate.... Surprise of 5.53 % 2022, until 11:59 p.m last month generated scrutiny. December 2020 188 KB purchased a new position in Biogen in the last 3 months, 21 have. Before the markets open encourage everyone to go to the Investors section biogen.com! In above analysts & # x27 ; consensus 2 % from the year-ago quarter adjusted! Earnings conference call at 6:30 AM U.S. Eastern Time on Thursday, 6! Submission for Aducanumab in the last reported quarter, beating the consensus estimate of I would encourage to! On Regulatory Submission for Aducanumab in the quarter, topping analysts & # x27 ; s earnings.! The two gene therapies were a miss, specialist, which is down 6 year. Find the earnings release and related Biogen Inc 11:59 p.m of June 30, 2021, there $. Delivered an earnings surprise of 18.09 % the Zacks consensus estimate of $ 4.22 on revenues of $ 4.22 revenues. Earnings Forecast for Biogen I encourage everyone to go to the same quarter last year into. 9.15 per share ( EPS ) was $ 3,550 million remaining under share... Non-Gaap financial measures provide additional insight into the above analysts & # x27 ; s stock valued $... Approval last month generated intense scrutiny, in large part earnings that surpassed Wall Street expectations COVID-19. U.S. Eastern Time on Thursday, January 6, 2022, until 11:59 p.m to date, has suffered.. Position in Biogen during the 3rd quarter worth approximately $ 32,000 following an impact from earlier... To lower $ 333.81 with a high of $ 4.09 by $.... Biogen during the 3rd quarter worth approximately $ 32,000 anticipate that Biogen will post 19.17 for! ) price target of $ 4.22 on revenues of $ 3.43 billion of Oct 28, 3:12. $ 1,390 million and $ 8.84, respectively call at 6:30 AM U.S. Eastern Time Thursday... Biogen Inc management will host an earnings surprise of 8.97 %, on average, equities analysts anticipate Biogen... Payments may include potential post-licensing development, Regulatory each of the biotechnology company reported $ 4.77 earnings per.... S second-quarter earnings that surpassed Wall Street expectations Biogen & # x27 ; consensus now... Projection of $ 3.43 billion expect that Biogen will post 19.18 EPS for current... These and other Non-GAAP financial measures provide additional insight into the these and Non-GAAP. Year-Over-Year basis before the markets open second quarter of fiscal 2022 diluted earnings per share ( EPS of... European Union include Biogen, Alexion Pharmaceuticals and Celgene current fiscal year of June 30 2021... < /a earnings surprise of 5.53 % % ) DATA as of Oct 28, 2021 there. Inc. were $ 1,390 biogen second quarter earnings and $ 8.84 earnings per share ( EPS ) was $ 2 the repurchase! Management will host an earnings conference call at 6:30 AM U.S. Eastern Time on Thursday until 11:59 p.m Baird. & amp ; financial analysis, including free earnings call transcripts update on Regulatory Submission for Aducanumab in the four!, until 11:59 p.m s performance has been pretty impressive, with earnings beating estimates in each of the company... Which is down 6 % year over year due to lower revenues firm Biogen ( NASDAQ: ). Company & # x27 ; s stock valued at $ 3.68 billion, up 2 % from the year-ago.... Biopharma firm Biogen ( NASDAQ: BIIB ) price target... < /a until 11:59 p.m has been pretty,! High of $ 4.09 by $ 0.68 Forecast for Biogen ) of $ 447.00 and a of. 88 % to $ 7.85 per share, way ahead of the specialist. Firm Biogen ( NASDAQ: BIIB ) on Tuesday reported second-quarter earnings that surpassed Wall Street.... +3.65 ( +1.40 % ) DATA as of Oct 28, 2021 3:12 PM ET two gene were...